Emerging targets and drugs of inflammatory bowel disease
10.16438/j.0513-4870.2021-1563
- VernacularTitle:治疗炎症性肠道疾病的新兴靶点与药物
- Author:
Chang-wei CHAI
;
Yi-xiang ZHANG
;
Hai-jing ZHANG
;
Lian-qiu WU
- Publication Type:Research Article
- Keywords:
inflammatory bowel disease;
ulcerative colitis;
Crohn's disease;
mechanism;
target
- From:
Acta Pharmaceutica Sinica
2022;57(5):1282-1288
- CountryChina
- Language:Chinese
-
Abstract:
Inflammatory bowel disease (IBD) is a chronic, repeated intestinal inflammatory disease. Clinically commonly used therapeutic drugs have some disadvantages, such as poor efficacy and many adverse reactions after long-term application. Although new biological therapies such as anti-tumor necrosis factor agents, overcome common adverse reactions, also have problems such as high price, difficult storage, drug resistance and recurrence after application. In recent years, many new therapeutic methods for inflammatory bowel disease have emerged, for example, modulators that inhibit lymphocyte migration (integrin inhibitors and sphingosine 1-phosphate receptor agonists) have been introduced into the clinical treatment of inflammatory bowel disease, inflammatory cytokine inhibitors (interleukin-23 inhibitors, Janus kinase inhibitors, phosphodiesterase inhibitors, etc.) and inhibitors targeting fibrosis and intestinal tissue degradation and remodeling (matrix metalloproteinase inhibitors) are also being evaluated in clinical trials of IBD. Based on the mechanisms of action, this paper intends to outline the current mainstream IBD therapies and some emerging drugs, and briefly introduce their targets to provide reference for IBD drug design and development.
